Strategic Initiative

Slingshot members are tracking this corporate initiative:

CymaBay In Ongoing Discussions With Potential Partners For The Phase 3 Development of Arhalofenate

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details From the Q4 Earnings Transcript: "Our strategic plan is to secure a commercial partnership with arhalofenate prior to the start of our Phase 3 program. Gout, as you know, is predominately treated by primary care physicians. Therefore, partnering arhalofenate with one or more companies that have a presence in the primary care market is a priority for us."  CymaBay, according to a press release, is in ongoing discussions with potential partners. 
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Mar 29, 2016
Projected Implementation:
Q4, 2016
Relevance Tracked Until:
Q4, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Potential Partnership, Phase 3 Development, Arhalofenate, Gout, Serum Uric Acid